ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS

• US 20090186041A1
• Filed: 04/18/2008
• Published: 07/23/2009
• Est. Priority Date: 11/15/2006
• Status: Active Grant

• Current Assignee: Eli Lilly and Company
• Original Assignee: Functional Genetics Incorporated
• Inventors: Goldbiatt, Michael, Kinch, Michael, LI, LIMIN
• Granted Patent: US 8,796,423 B2
• Time in Patent Office: Days
• US Class Current: 424/185.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.

Claims

1-17. -17. (canceled)

18. A method of inducing the expression of antibodies to TSG101 in a mammal, comprising:

Administering to said mammal an immunogen, wherein said immunogen is antigenic in said mammal whereby said mammal is caused to generate antibodies in response thereto, said immunogen being administered to said mammal in an amount effective to induce said generation of antibodies, and wherein said antibodies bind to TSG101.

19. A method of vaccinating a mammal so as to generate a circulating titer of anti-TSG101 antibodies in said mammal effective to inhibit the proliferation of a virus in the cells of said mammal, said method comprising:

Administering to said mammal a TSG101 immunogen which induces in said mammal the generation of antibodies thereto, wherein said antibodies bind to TSG101, and wherein said administration is repeated with sufficient frequency to maintain said titer at a level effective to the proliferation of a virus in the cells of said mammal.

20. The method of claim 19, wherein said immunogen is a fragment of a TSG101 protein which is antigenic in said mammal.

21. The method of claim 20, wherein said fragment does not comprise a UEV domain.

22. The method of claim 20, wherein said fragment comprises a coiled coil domain of a TSG101 protein.

23. The method of claim 20, wherein said fragment comprises the C-terminus region of a TAG101 protein and is from 5-100 amino acids in length.

24. The method of claim 23, wherein said fragment comprises the amino acid sequence of SEQ. ID No. 3.

25. The method of claim 19, wherein said immunogen is administered together with an immunostimulatory agent.

26. The method of claim 19, wherein said immunogen is administered to said mammal either by the inoculation of said mammal with said immunogen, or the introduction into said mammal nucleic acids which induce the expression by said mammal of said immunogen, and introduction of said immunogen into the systemic circulation of said mammal.